BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie H, Yu H, Tian S, Yang X, Wang X, Yang Z, Wang H, Guo Z. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis. Oncotarget 2017;8:100508-23. [PMID: 29245997 DOI: 10.18632/oncotarget.20119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Huo Y, Wang Q, Liu Y, Wang J, Li Q, Li Z, Dong Y, Huang Y, Wang L. A temperature-sensitive phase-change hydrogel of topotecan achieves a long-term sustained antitumor effect on retinoblastoma cells. Onco Targets Ther 2019;12:6069-82. [PMID: 31534347 DOI: 10.2147/OTT.S214024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Feng F, Jiang Q, Cao S, Cao Y, Li R, Shen L, Zhu H, Wang T, Sun L, Liang E, Sun H, Chai Y, Li X, Liu G, Yang R, Yang Z, Yang Y, Xin S, Li BA. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Biochim Biophys Acta Gen Subj 2018;1862:1017-30. [PMID: 29369785 DOI: 10.1016/j.bbagen.2018.01.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]
3 Wang J, Liu R, Zhao Y, Ma Z, Sang Z, Wen Z, Yang X, Xie H. Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. Front Oncol 2021;11:743055. [PMID: 34513717 DOI: 10.3389/fonc.2021.743055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zou XZ, Hao JF, Zhou XH. Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation. Front Oncol 2021;11:796152. [PMID: 34900747 DOI: 10.3389/fonc.2021.796152] [Reference Citation Analysis]
5 Shao QP, Wei C, Yang J, Zhang WZ. miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway. Onco Targets Ther 2020;13:7213-27. [PMID: 32801751 DOI: 10.2147/OTT.S246471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q, Hou J. A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma. Front Oncol 2021;11:783194. [PMID: 34869036 DOI: 10.3389/fonc.2021.783194] [Reference Citation Analysis]
7 Wei L, Lun Y, Zhou X, He S, Gao L, Liu Y, He Z, Li B, Wang C. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacol Res 2019;143:73-85. [PMID: 30862605 DOI: 10.1016/j.phrs.2019.03.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
8 Feng F, Jiang Q, Jia H, Sun H, Chai Y, Li X, Rong G, Zhang Y, Li Z. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. Pharmacol Res 2018;135:89-101. [PMID: 29959032 DOI: 10.1016/j.phrs.2018.06.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
9 Abouelezz K, Khanapara D, Batiha GE, Ahmed EA, Hetta HF. Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries. Cancer Manag Res 2020;12:12239-48. [PMID: 33273860 DOI: 10.2147/CMAR.S280631] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
11 Xie H, Tian S, Cui L, Yan J, Bai Y, Li X, Wang M, Zhang F, Duan F. Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma. Cancer Manag Res 2019;11:4065-73. [PMID: 31118814 DOI: 10.2147/CMAR.S195485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
12 Tsuchiya A, Ogawa M, Watanabe T, Takeuchi S, Kojima Y, Watanabe Y, Kimura N, Hayashi K, Yokoyama J, Terai S. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma. Heliyon 2019;5:e01325. [PMID: 30911692 DOI: 10.1016/j.heliyon.2019.e01325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
13 Xie H, Tian S, Yu H, Yang X, Liu J, Wang H, Feng F, Guo Z. A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma. Onco Targets Ther 2018;11:3257-65. [PMID: 29910621 DOI: 10.2147/OTT.S165000] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
14 Iezzi R, Pompili M, Posa A, Carchesio F, Siciliano M, Annicchiarico BE, Agnes S, Giuliante F, Garcovich M, Cerrito L, Ponziani FR, Basso M, Cassano A, Rapaccini GL, De Gaetano AM, Gasbarrini A, Manfredi R; HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? Eur J Radiol 2019;114:32-7. [PMID: 31005173 DOI: 10.1016/j.ejrad.2019.02.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
15 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
16 Feng YQ, Li BA, Feng F, Chen YS, Ren YX, Zhang H, Cao S. Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. Onco Targets Ther 2020;13:7165-76. [PMID: 32801748 DOI: 10.2147/OTT.S244474] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
17 Tian G, Yang S, Yuan J, Threapleton D, Zhao Q, Chen F, Cao H, Jiang T, Li L. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis. BMJ Open. 2018;8:e021269. [PMID: 30341113 DOI: 10.1136/bmjopen-2017-021269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
18 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li J, Zhao J, Wang H, Li X, Liu A, Qin Q, Li B. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. Onco Targets Ther 2018;11:5885-94. [PMID: 30271172 DOI: 10.2147/OTT.S179509] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
21 Meng D, Lei H, Zheng X, Han Y, Sun R, Zhao D, Liu R. A temperature-sensitive phase-change hydrogel of tamoxifen achieves the long-acting antitumor activation on breast cancer cells. Onco Targets Ther 2019;12:3919-31. [PMID: 31213826 DOI: 10.2147/OTT.S201421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
22 Hou FJ, Guo LX, Zheng KY, Song JN, Wang Q, Zheng YG. Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Onco Targets Ther 2019;12:6685-97. [PMID: 31695406 DOI: 10.2147/OTT.S215103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]